Perindopres A is a new medicinal product for the treatment of arterial hypertension20 January 2020
Perindopres A is a new medicinal product of the Perindopres line by the Darnitsa Pharmaceutical Company for patients with hypertension.
In Ukraine, over 10 million people suffer from hypertension. Blood pressure control in hypertension plays a key role in preventing cardiovascular complications. The use of a fixed-dose combination of antihypertensive agents (i.e. a combination of several active substances in a single dosage form) is optimal for effective blood pressure control and convenient for patients. Thus, Perindopres A is a dual fixed-dose combination of antihypertensive agents. Unlike Perindopres, which contains one active substance, perindopril, Perindopres A is supplemented with one more active substance, amlodipine.
The results of clinical studies indicate that the use of a fixed-dose combination of perindopril and amlodipine allows more effectively reducing blood pressure compared to the monotherapy with either component of the combination.
Perindopres A is available in tablet form in two doses: 4 mg/5 mg and 8 mg/10 mg, 30 tablets in a pack.
The product is used only upon a doctor’s prescription and is available upon prescription.
Registration Certificates No. UA/17768/01/01, No. UA/17768/01/02.
Information for medical and pharmaceutical workers only for professional use. The information is presented in an abbreviated form. For complete information on the medicinal product and possible adverse effects, refer to the instructions for medical use. The site is a specialized publication intended for medical and pharmaceutical professionals. You should consult your doctor before using this medicinal product. Self-medication can be dangerous to your health.